Q2 2026 Viking Therapeutics Inc Earnings Call Transcript
Key Points
- VK2735 Phase III VANQUISH program is fully enrolled and advancing on track, with both obesity and obesity/type 2 diabetes trials progressing.
- Oral VK2735 Phase III trials expected to initiate in Q4 2026, positioning it as a potential first-to-market oral dual GLP-1/GIP agonist.
- Novel maintenance dosing study for VK2735 is nearing completion, with results expected later this quarter, exploring less frequent dosing regimens.
- New dual amylin and calcitonin receptor agonist, VK3019, entered Phase I clinical development, expanding the obesity pipeline.
- Strong balance sheet with over $500 million in cash, expected to fund key milestones including completion of Phase III trials.
- Key executive hires, including a Chief Commercial Officer and Chief Medical Officer, strengthen commercial and clinical leadership.
- Net loss increased significantly to $128.1 million in Q2 2026 from $65.6 million in Q2 2025, driven by higher R&D expenses.
- Cash and short-term investments decreased to $502 million from $706 million at year-end 2025, reflecting high cash burn.
- Phase III oral VK2735 trial design details remain undisclosed, creating uncertainty about dosing and enrollment targets.
- Maintenance study results may be difficult to compare with competitor trials due to different study designs and shorter duration.
- Early-stage VK3019 program faces uncertainty, with no clear go/no-go decision criteria until Phase I MAD data in 2027.
Good day, and welcome to the Viking Therapeutics second quarter 2026 financial results conference call. (Operator Instructions) And as a reminder, this conference call is being recorded today, July 29, 2026.
I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.
Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, July 29, 2026, will contain forward-looking statements under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995 including statements about Viking's expectations regarding its development activities, timelines, and milestones.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
